Back to Search Start Over

Neolymphostin A Is a Covalent Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor That Employs an Unusual Electrophilic Vinylogous Ester.

Authors :
Castro-Falcón G
Seiler GS
Demir Ö
Rathinaswamy MK
Hamelin D
Hoffmann RM
Makowski SL
Letzel AC
Field SJ
Burke JE
Amaro RE
Hughes CC
Source :
Journal of medicinal chemistry [J Med Chem] 2018 Dec 13; Vol. 61 (23), pp. 10463-10472. Date of Electronic Publication: 2018 Nov 28.
Publication Year :
2018

Abstract

Using a novel chemistry-based assay for identifying electrophilic natural products in unprocessed extracts, we identified the PI3-kinase/mTOR dual inhibitor neolymphostin A from Salinispora arenicola CNY-486. The method further showed that the vinylogous ester substituent on the neolymphostin core was the exact site for enzyme conjugation. Tandem MS/MS experiments on PI3Kα treated with the inhibitor revealed that neolymphostin covalently modified Lys802 with a shift in mass of +306 amu, corresponding to addition of the inhibitor and elimination of methanol. The binding pose of the inhibitor bound to PI3Kα was modeled, and hydrogen-deuterium exchange mass spectrometry experiments supported this model. Against a panel of kinases, neolymphostin showed good selectivity for PI3-kinase and mTOR. In addition, the natural product blocked AKT phosphorylation in live cells with an IC <subscript>50</subscript> of ∼3 nM. Taken together, neolymphostin is the first reported example of a covalent kinase inhibitor from the bacterial domain of life.

Details

Language :
English
ISSN :
1520-4804
Volume :
61
Issue :
23
Database :
MEDLINE
Journal :
Journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
30380865
Full Text :
https://doi.org/10.1021/acs.jmedchem.8b00975